ArticleThe Journal of infectious diseases2004
Neutralizing antibodies in patients with severe acute respiratory syndrome-associated coronavirus infection.
Article in The Journal of infectious diseases, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 98 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
98 citing papers in PubMed, 1 synthesis or guideline pooled it, 151 citations in OpenAlex.
- A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity.Nature communications · 2020Pooled it
- Can human IgG subclasses distinguish between confirmed and unconfirmed SARS-CoV-2 infections?Journal, genetic engineering & biotechnology · 2024Article
- Clinical and laboratory features in health care volunteers with inactivated SARS-CoV-2 vaccination.Turkish journal of medical sciences · 2023Article
- Characterization and immunogenicity of SARS-CoV-2 spike proteins with varied glycosylation.Vaccine · 2022Article
- COVID-19 and plasma cells: Is there long-lived protection?Immunological reviews · 2022Review
- From Pandemicity to Endemicity: The Journey of SARS-CoV-2.Journal of epidemiology and global health · 2022Article
- The impact of lymphoid memory cells in different ages of COVID-19 patients.Gene reports · 2022Review
- Clinical course impacts early kinetics,magnitude, and amplitude of SARS-CoV-2 neutralizing antibodies beyond 1 year after infection.Cell reports. Medicine · 2022Article
- Clinical significance of serum IgM and IgG levels in COVID-19 patients in Hubei Province, China.Journal of intensive medicine · 2022Article
- Identification and Development of Therapeutics for COVID-19.mSystems · 2021Article
- Neutralizing antibody responses over time in demographically and clinically diverse individuals recovered from SARS-CoV-2 infection in the United States and Peru: A cohort study.PLoS medicine · 2021Article
- Pharmaceutical Aspects and Clinical Evaluation of COVID-19 Vaccines.Immunological investigations · 2021Review
- A comprehensive review of COVID-19 biology, diagnostics, therapeutics, and disease impacting the central nervous system.Journal of neurovirology · 2021Review
- Key Considerations for the Development of Safe and Effective SARS-CoV-2 Subunit Vaccine: A Peptide-Based Vaccine Alternative.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Review
- COVID-19 versus SARS: A comparative review.Journal of infection and public health · 2021Review
- Presence and strength of binding of IgM, IgG and IgA antibodies against SARS-CoV-2 during CoViD-19 infection.Biosensors & bioelectronics · 2021Article
- Moderate vs. mild cases of overseas-imported COVID-19 in Beijing: a retrospective cohort study.Scientific reports · 2021Article
- Simultaneous CD8Vaccines · 2021Article
- Article
- Functional and Structural Characterization of SARS-Cov-2 Spike Protein: AnEthiopian journal of health sciences · 2021Article
38 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSevere acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) is the principal etiologic agent of SARS. We analyzed serum samples obtained from 623 patients with SARS in Beijing, to determine whether infection with SARS-CoV can elicit neutralizing antibodies (NAbs).
methodsWe developed a highly sensitive and safe neutralization assay using the SARS-CoV pseudotyped virus and used this assay to determine the titers of the NAbs in serum samples from patients with SARS.
resultsWe found that 85.9% of serum samples contained NAbs against SARS-CoV and that most of the NAb activities could be attributed to immunoglobulin G. The NAbs became detectable first at 5-10 days after the onset of symptoms, and their levels peaked at 20-30 days and then were sustained for >150 days. The serum samples could neutralize the pseudotype particles bearing the spike glycoproteins from different SARS-CoV strains, suggesting that the NAbs to SARS-CoV were broadly reactive.
conclusionsNAbs to SARS-CoV are broadly elicited in patients with SARS and, according to their kinetics, may correlate with viral load during the early stages of the disease. These results suggest that it is possible to develop effective vaccines against SARS and that NAbs provide a potential strategy for treating patients with SARS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.